Literature DB >> 16361412

Dendritic cells pulsed with hepatitis C virus NS3 protein induce immune responses and protection from infection with recombinant vaccinia virus expressing NS3.

Hong Yu1, Hui Huang, Jim Xiang, Lorne A Babiuk, Sylvia van Drunen Littel-van den Hurk.   

Abstract

Infections with Hepatitis C virus (HCV) pose a serious health problem worldwide. In this study, the hypothesis that adoptive transfer of dendritic cells (DCs) pulsed with HCV NS3 protein and matured with an oligodeoxynucleotide (ODN) containing CpG motifs (CpG) ex vivo would initiate potent HCV-specific protective immune responses in vivo was tested. NS3 protein was efficiently transduced into DCs and treatment of DCs with CpG ODN induced phenotypic maturation and specifically increased the expression of CD40. DCs matured with CpG ODN produced higher interleukin 12 levels and a stronger allogeneic T-cell response compared with untreated DCs. Notably, there were no differences between NS3-pulsed DCs and DCs pulsed with a control protein with respect to phenotype, cytokine production or mixed lymphocyte reaction, indicating that transduction with NS3 protein did not impair DC functions. Compared with the untreated NS3-pulsed DCs, the NS3-pulsed DCs matured with CpG ODN induced stronger cellular immune responses including enhanced cytotoxicity, higher interferon-gamma production and stronger lymphocyte proliferation. Upon challenge with a recombinant vaccinia virus expressing NS3, all mice immunized with NS3-pulsed DCs showed a significant reduction in vaccinia virus titres when compared with mock-immunized mice. However, the NS3-pulsed DCs matured with CpG ODN induced higher levels of protection compared with the untreated NS3-pulsed DCs. These data are the first to show that NS3-pulsed DCs induce specific immune responses and provide protection from viral challenge, and also demonstrate that CpG ODNs, which have a proven safety profile, would be useful in the development of DC vaccines.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16361412     DOI: 10.1099/vir.0.81423-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

Review 1.  Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments.

Authors:  Philip Wintermeyer; Jack R Wands
Journal:  J Gastroenterol       Date:  2007-06-29       Impact factor: 7.527

2.  Vaccination with dendritic cells pulsed with hepatitis C pseudo particles induces specific immune responses in mice.

Authors:  Kilian Weigand; Franziska Voigt; Jens Encke; Birgit Hoyler; Wolfgang Stremmel; Christoph Eisenbach
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

3.  Immunogenicity of a bovine herpesvirus 1 glycoprotein D DNA vaccine complexed with bovine neutrophil beta-defensin 3.

Authors:  Sarah Mackenzie-Dyck; Laura Latimer; Ethel Atanley; Jennifer Kovacs-Nolan; Sam Attah-Poku; Lorne A Babiuk; Sylvia van Drunen Littel-van den Hurk
Journal:  Clin Vaccine Immunol       Date:  2014-11-05

4.  A phase I clinical trial of dendritic cell immunotherapy in HCV-infected individuals.

Authors:  Eric J Gowans; Stuart Roberts; Kathryn Jones; Irene Dinatale; Philippe A Latour; Brendan Chua; Emily M Y Eriksson; Ruth Chin; Shuo Li; Dominic M Wall; Rosemary L Sparrow; Jude Moloney; Maureen Loudovaris; Rosemary Ffrench; H Miles Prince; Derek Hart; Weng Zeng; Joseph Torresi; Lorena E Brown; David C Jackson
Journal:  J Hepatol       Date:  2010-06-20       Impact factor: 25.083

5.  Hepatitis C virus modulates human monocyte-derived dendritic cells.

Authors:  E A Eksioglu; J R Bess; H Zhu; Y Xu; H-J Dong; J Elyar; D R Nelson; C Liu
Journal:  J Viral Hepat       Date:  2010-11       Impact factor: 3.728

6.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

7.  Dendritic cell function during chronic hepatitis C virus and human immunodeficiency virus type 1 infection.

Authors:  Zheng Fan; Xiao-Li Huang; Pawel Kalinski; Stephen Young; Charles R Rinaldo
Journal:  Clin Vaccine Immunol       Date:  2007-07-18

Review 8.  Current status and future directions in the management of chronic hepatitis C.

Authors:  Wosen Aman; Shaymaa Mousa; Gamal Shiha; Shaker A Mousa
Journal:  Virol J       Date:  2012-03-02       Impact factor: 4.099

9.  Regulatory dendritic cells: there is more than just immune activation.

Authors:  Susanne V Schmidt; Andrea C Nino-Castro; Joachim L Schultze
Journal:  Front Immunol       Date:  2012-09-04       Impact factor: 7.561

10.  Construction and Immunogenicity Analysis of Hepatitis C Virus (HCV) Truncated Non-Structural Protein 3 (NS3) Plasmid Vaccine.

Authors:  Mohammad-Hassan Pouriayevali; Taravat Bamdad; Mohammad-Reza Aghasadeghi; Seyed Mehdi Sadat; Farzaneh Sabahi
Journal:  Jundishapur J Microbiol       Date:  2016-03-19       Impact factor: 0.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.